CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer

SpringerPlus

Volumn 2, Issue 1, 2013, Pages 1-5

  Love, Richard R ^a   Desta, Zuerenesay ^a   Flockhart, David ^a   Skaar, Todd ^a   Ogburn, Evan T ^a   Ramamoorthy, Anuradha ^a   Uy, Gemma B ^a   Laudico, Adriano V ^a   van Dinh, Nguyen ^a   Quang, Le Hong ^a   van To, Ta ^a   Young, Gregory S ^a   Hade, Erinn ^a   Jarjoura, David ^a  

^a International Breast Cancer Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876563989     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-52     Document Type: Article

References (14)

1. Ahamed A, Ali SM, Ahmad MU et al (2010) Orally administered endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res Treat 122:579-584
2. Bergstralh E, Kosanke J, Jacobsen S (1996) Software for optimal matching in observational studies. Epidemiology 7(3):331-332
3. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74
4. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229-243
5. Desta Z, Ward BA, Soukhova NV et al (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075
6. Dezentjé VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H (2009) Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 15:15-21
7. Hayes DF, Stearns V, Rae J et al (2008) A model citizen? Is tamoxifen more effective than aromatase inhibitor if we pick the right patients? J Natl Cancer Inst 100:610-613
8. Irvin WJ, Walko CM, Weck KE et al (2011) Genotype-guided Tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 29:3232-3239
9. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97(1):30-39
10. Kiyotani K, Mushiroda T, Imamura CK et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28(8):1287-1293. doi:10.1200/JCO.2009.25.7246
11. Lash T, Rosenberg CL (2010) Evidence and practice regarding the role of CYP2D6 inhibition in decisions about tamoxifen therapy. J Clin Oncol 28:1273-1275
12. Pepe M, Feng Z, Janes H, Bossuyt P, Potter J (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100(20):1432-1438
13. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17(2):93-101
14. Veiga MI, Asimus S, Ferreira PE, Martins JP, Cavaco I, Ribeiro V, Hai TN, Petzold MG, Björkman A, Ashton M, Gil JP (2009) Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol 65:355-363